Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Derman BA, et al. Among authors: gurbuxani s. JAMA Oncol. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424. JAMA Oncol. 2022. PMID: 35862034 Free PMC article. Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Jasielec JK, et al. Among authors: gurbuxani s. Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522. Blood. 2020. PMID: 32735641 Free PMC article. Clinical Trial.
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. Larson SM, et al. Among authors: gurbuxani s. Leuk Lymphoma. 2012 Mar;53(3):445-50. doi: 10.3109/10428194.2011.621562. Leuk Lymphoma. 2012. PMID: 21913806
Red cell morphology in sickle cell disease.
Parilla M, Gurbuxani S. Parilla M, et al. Among authors: gurbuxani s. Blood. 2020 Oct 15;136(16):1893. doi: 10.1182/blood.2020007602. Blood. 2020. PMID: 33057703 Free article. No abstract available.
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
Tariq H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, Segal J, Gurbuxani S, Helenowski IB, Zhang H, Sukhanova M, Lu X, Altman JK, Chen QC, Behdad A. Tariq H, et al. Among authors: gurbuxani s. Br J Haematol. 2022 Jun;197(6):736-744. doi: 10.1111/bjh.18154. Epub 2022 Mar 18. Br J Haematol. 2022. PMID: 35304738
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.
Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. Godley LA, et al. Among authors: gurbuxani s. Semin Oncol. 2011 Apr;38(2):215-24. doi: 10.1053/j.seminoncol.2011.01.003. Semin Oncol. 2011. PMID: 21421111 Free PMC article. Review.
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.
Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews JM, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, Chen J. Jiang X, et al. Among authors: gurbuxani s. Cancer Cell. 2012 Oct 16;22(4):524-35. doi: 10.1016/j.ccr.2012.08.028. Cancer Cell. 2012. PMID: 23079661 Free PMC article.
111 results